GB2095

GB2095 is an orally active and selective galectin-3 inhibitor. GB2095 shows superior selectivity for both human (KD = 0.036 μM) and mouse galectin-3 (KD = 0.35 μM) over other galectins (such as h-Gal-1/4N/4C/8N/8C/9N/9C and m-galectin-1) . GB2095 inhibits tumor growth in syngeneic mouse models of breast and melanoma cancers. GB2095 can be used for breast and melanoma cancer research[1].

Product Specifications

CAS Number

[2574415-75-9]

UNSPSC

12352005

Target

Galectin

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

98.92

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O[C@@H]1[C@@H](N2C=C(C3=CC(F)=C(C(F)=C3)Cl)C=N2)[C@H]([C@H](O[C@@H]1SC4=CN=CC(Br)=C4)CO)O

Molecular Formula

C20H17BrClF2N3O4S

Molecular Weight

548.79

References & Citations

[1]Peterson K, et al., Development and Characterization of a High-Affinity Selective Galectin-3 Mouse Tool Compound in Mouse Models of Cancer. J Med Chem. 2024 Dec 26;67 (24) :21905-21915.